Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Practical experience of ustekinumab in the treatment of psoriasis: Experience from a multicentre, retrospective case cohort study across the U.K. and Ireland

Laws, P. M., Downs, A. M., Parslew, R., Dever, B., Smith, C. H., Barker, J. N., Moriarty, B., Murphy, R., Kirby, B., Burden, A. D., McBride, S., Anstey, Alexander Vincent, O'Shea, S., Ralph, N., Buckley, C., Griffiths, C. E. M. and Warren, R. B. 2012. Practical experience of ustekinumab in the treatment of psoriasis: Experience from a multicentre, retrospective case cohort study across the U.K. and Ireland. British Journal Of Dermatology 166 (1) , pp. 189-195. 10.1111/j.1365-2133.2011.10638.x

Full text not available from this repository.

Abstract

Background There are limited data on the use of ustekinumab outside of clinical trials. Objectives To assess the efficacy and safety of ustekinumab in patients with severe psoriasis attending 10 dermatology centres in the U.K. and Ireland. Methods A retrospective case-note review of 129 patients with psoriasis treated with ustekinumab. Results Baseline Psoriasis Area and Severity Index (PASI) was 22Æ9 ± 10Æ1 (mean ± SD). After 16 weeks of treatment with ustekinumab PASI 75 (75% reduction in PASI) was observed in 63Æ0% (n = 80⁄127) of patients, although four patients required concomitant therapy at the 16-week time point. Previous biologic use did show a small, non-significant trend towards treatment failure. A PASI 75 response was seen in 29Æ4% (n = 5⁄17) of individuals weighing 90– 100 kg and treated with the standard 45 mg ustekinumab dose compared with PASI 75 of 70Æ3%, 71Æ4%, 75Æ0% and 55Æ6% for weight groups < 80, 80–90, 100–110 and > 110 kg, respectively (P = 0Æ024). Ustekinumab therapy was well tolerated; serious adverse events were observed in 2Æ3% (n = 3⁄129) of patients. Conclusions Ustekinumab is a novel biologic agent for psoriasis. When used in everyday clinical practice it demonstrates high levels of short-term therapeutic efficacy with an acceptable short-term safety profile.

Item Type: Article
Date Type: Publication
Status: Published
Schools: Medicine
Subjects: R Medicine > R Medicine (General)
R Medicine > RL Dermatology
Publisher: Blackwell Publishing
ISSN: 0007-0963
Last Modified: 19 Mar 2016 23:12
URI: http://orca-mwe.cf.ac.uk/id/eprint/42826

Citation Data

Cited 14 times in Google Scholar. View in Google Scholar

Cited 22 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item Edit Item